Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value-Reference-Cited by-同舟云学术

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

Published:2009-07-30 Issue:9 Volume:23 Page:1628-1633
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hochhaus A,Müller M C,Radich J,Branford S,Kantarjian H M,Hanfstein B,Rousselot P,Kim D-W,Lipton J H,Bleickardt E,Lambert A,Hughes T P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2009156.pdf

Reference28 articles.

1. Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet 2007; 370: 342–350.

2. Kavalerchik E, Goff D, Jamieson CH . Chronic myeloid leukemia stem cells. J Clin Oncol 2008; 26: 2911–2915.

3. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37.

4. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505.

5. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200–1206.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia;Haematologica;2023-01-26

2. Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation;Chemical Biology & Drug Design;2020-10-29

3. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice;Leukemia & Lymphoma;2020-10-06

4. Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison;Scientific Reports;2018-08-17

5. Rare Acute Leukemias;Textbook of Uncommon Cancer;2017-03-11